Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure

Cardiol Rev. 2013 May-Jun;21(3):151-4. doi: 10.1097/CRD.0b013e3182749cdb.

Abstract

The development of cardiac-specific adeno-associated viral vectors capable of long-term transgenic expression has opened new avenues in the therapeutic approach to heart failure. Failing cardiomyocytes demonstrate altered calcium-handling secondary to depressed expression and activity of myocardial sarcoendoplasmic reticulum calcium ATPase 2a (SERCA2a). This observation has led to a large body of research investigating the therapeutic utility of SERCA2a gene therapy in heart failure.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Genetic Therapy / methods*
  • Heart Failure / enzymology
  • Heart Failure / therapy*
  • Humans
  • Rats
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / antagonists & inhibitors*
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / genetics
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / physiology
  • Sheep

Substances

  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • ATP2A2 protein, human